Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study.
critically ill patients
dysglycemia
hyperglycemia
insulin glargine
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
11
2019
accepted:
20
02
2020
entrez:
27
3
2020
pubmed:
27
3
2020
medline:
27
3
2020
Statut:
epublish
Résumé
We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU). A total of 110 patients randomly received adjuvant insulin glargine 15 IU/day (glargine) or placebo (control), in addition to daily infusion of insulin to maintain glucose levels at a target of 140-180 mg/dL. End points were mean and variance of blood glucose and frequency of hypoglycemia, hyperglycemia, ICU stay, and mortality. Data were analyzed with repeated-measures ANOVA and Mann-Whitney Average daily glucose level was significantly less in the glargine group than controls ( Addition of insulin glargine to routine protocols more effectively reduces glucose levels and decreases incidence of hyperglycemic episodes and regular insulin usage. This adjustment may be associated with decreases in duration of ICU stay or increases in hypoglycemic events.
Identifiants
pubmed: 32210600
doi: 10.2147/DMSO.S240645
pii: 240645
pmc: PMC7073596
doi:
Types de publication
Case Reports
Langues
eng
Pagination
671-678Informations de copyright
© 2020 Nader et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Diabetes Res Clin Pract. 2011 Dec;94(3):340-51
pubmed: 21978840
Acad Emerg Med. 2015 Jun;22(6):657-62
pubmed: 26013711
Saudi Med J. 2010 Mar;31(3):331-2
pubmed: 20231945
JPEN J Parenter Enteral Nutr. 2017 Sep;41(7):1110-1118
pubmed: 27091835
Ann Nutr Metab. 2017;71(3-4):183-194
pubmed: 29017173
Gac Med Mex. 2016 Nov - Dec;152(6):761-769
pubmed: 27861474
Indian J Crit Care Med. 2016 Feb;20(2):67-71
pubmed: 27076705
Indian J Crit Care Med. 2018 Mar;22(3):174-179
pubmed: 29657375
Endocr Pract. 2007 May-Jun;13(3):225-31
pubmed: 17599852
Intensive Care Med. 2007 Jul;33(7):1173-1178
pubmed: 17508198
Endocr Pract. 2013 May-Jun;19(3):485-93
pubmed: 23425653
Crit Care. 2014 Apr 30;18(2):R86
pubmed: 24886864
Crit Care Med. 2007 Oct;35(10):2262-7
pubmed: 17717490
Anesth Pain Med. 2016 Jan 31;6(1):e33849
pubmed: 27110538
Pharmacotherapy. 2015 Feb;35(2):148-57
pubmed: 25689245
N Engl J Med. 2001 Nov 8;345(19):1359-67
pubmed: 11794168
J Intensive Care Med. 2018 May;33(5):317-321
pubmed: 27821581
J Clin Diagn Res. 2015 May;9(5):OC01-5
pubmed: 26155506
Acta Diabetol. 2006 Aug;43(2):57-60
pubmed: 16865331
Crit Care Med. 2012 Dec;40(12):3251-76
pubmed: 23164767
Diabetes Technol Ther. 2006 Dec;8(6):609-16
pubmed: 17109592